The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Health resource utilization (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BM): Results of a prospective multinational observational study.
A. Bahl
Consultant or Advisory Role - Amgen
Honoraria - Amgen
H. Hoefeler
Honoraria - Amgen
I. Duran
Consultant or Advisory Role - Amgen
G. Hechmati
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
C. Garzon-Rodriguez
Consultant or Advisory Role - Amgen
D. Lueftner
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Expert Testimony - Amgen
J. Ashcroft
Consultant or Advisory Role - Amgen
Honoraria - Amgen
R. Wei
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
E. Thomas
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
V. Lorusso
No relevant relationships to disclose